apceth, University of Cologne deal

apceth partnered with the university’s Center for Molecular Medicine Cologne to develop immunotherapies to treat solid tumors and hematological malignancies. The partners will combine CAR T cells against multiple undisclosed tumor-associated antigens developed at the university with mesenchymal stem cells developed at apceth. The partners believe the stem cells will promote the local activation of the CAR T cells within tumors and therefore increase the specificity of the CAR T cells. ...